← IDXX Overview
8-KJanuary 13, 20261/13/26
IDXX — 8-K Filing
Track for AlertsIDXX 8-K Summary
On January 13, 2026, IDEXX Laboratories INC /DE filed an 8-K covering 3 items, including Departure / Election of Directors or Officers (Item 5.02), Financial Statements and Exhibits (Item 9.01), and 1 additional item. Primary disclosure: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers CEO Transition. On January 11, 2026, Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc.
8-K Items Disclosed
Item 5.02 — Departure / Election of Directors or Officers
Officer or director change — appointment, resignation, retirement, or termination, plus compensation arrangements.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers CEO Transition. On January 11, 2026, Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) of his intent to step down as the Company’s President and Chief Executive Officer effective as of May 12, 2026 (the “Transition Date”) and retire from the Company and the Company’s Board of the Directors (the “Board”) immediately following the Company’s annual meeting of shareholders in May 2027 (the “Retirement Date”). On January 13, 2026, the Company announced that effective as of the Transition Date Mr.
Item 7.01 — Regulation FD Disclosure
Voluntarily-disclosed material information under Regulation FD (e.g., investor presentation, conference talk).
A copy of the press release dated January 13, 2026, announcing these matters is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 — Financial Statements and Exhibits
Press releases, exhibits, and supporting documents attached to this filing.
10.1
Letter Agreement by and between Michael (Mike) Erickson, PhD, and IDEXX Laboratories, Inc., dated January 12, 2026.
10.2
Amended and Restated Change in Control Agreement by and between Michael (Mike) Erickson, PhD, and IDEXX Laboratories, Inc., dated January 12, 2026.
10.3
Letter Agreement by and between Jonathan (Jay) Mazelsky and IDEXX Laboratories, Inc., dated January 12, 2026.
99.1
Press Release issued by IDEXX Laboratories, Inc. on January 13, 2026.
104
Cover Page Interactive Data File (embedded within Inline XBRL document)
Structured financials are not available for this filing. View the original on SEC EDGAR for details.
Current DredgeCap Risk Profile
2.5/10
LOW RISK
Dilution Risk
LOW1.5/10
Liquidity Risk
LOW2.5/10
Debt Toxicity
LOW2.0/10
Profitability Risk
LOW2.0/10
Going Concern✓ Not flagged
The risk profile above reflects the latest cached DredgeCap analysis for IDXX. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open IDXX's company page.
What is a 8-K?
A current report disclosing a material event that occurred between regular reporting periods. Companies are required to file an 8-K within four business days of certain events including earnings releases, executive changes, acquisitions, debt obligations, restructurings, and material agreements. Each 8-K specifies one or more 'Items' identifying which event triggered the filing.
Form-type explainers and 8-K item descriptions are derived from SEC documentation. Financial values are extracted from SEC-tagged XBRL — see the "Source filings" list above each table for direct EDGAR links to every cited filing. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.